The global primary sclerosing cholangitis (PSC) market is on an impressive growth trajectory, with forecasts estimating a market valuation of USD 314.26 million by 2033. This robust expansion is ...

Abstracts include a presidential plenary-selected Phase 2 study evaluating the combination of obeticholic acid and ...

Pruritus is less common with alcohol-induced liver diseases and nonalcoholic ... such as primary biliary cirrhosis, primary sclerosing cholangitis, and obstructive biliary disease.

This can include forms of cholangitis that can cause inflammation of the bile ducts, such as primary sclerosing cholangitis. Exposure to toxins or drug or alcohol use could also lead to inflammation ...

For more information on the press release, click on the following link : Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant ...

1 CCL24 blockade alters the proteomic profile of patients with primary sclerosing cholangitis and down-regulates central disease processes, T Snir, R Greenman, R Aricha, I Vaknin, M Frankel ...

Ipsen’s elafibranor has shown promise as a treatment for primary sclerosing cholangitis (PSC), a rare liver disease that currently has no approved treatment options. Results from the phase 2 ELMWOOD ...